Influence of di-butyltin dilaurate on brain neurotransmitter systems and behavior in rats

1988 ◽  
Vol 61 (5) ◽  
pp. 373-377 ◽  
Author(s):  
M. S. Alam ◽  
R. Husain ◽  
S. P. Srivastava ◽  
P. K. Seth
Keyword(s):  
Neurotransmitter Systems ◽  
Brain Neurotransmitter ◽  
And Behavior

scholarly journals Housing and road transport modify the brain neurotransmitter systems of pigs: Do pigs raised in different conditions cope differently with unknown environments?

PLoS ONE ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. e0210406 ◽  
Author(s):  
Laura Arroyo ◽  
Daniel Valent ◽  
Ricard Carreras ◽  
Raquel Peña ◽  
Josefa Sabrià ◽  
...  
Keyword(s):  
Road Transport ◽  
Neurotransmitter Systems ◽  
Unknown Environments ◽  
Brain Neurotransmitter ◽  
The Brain

Alzheimer's Disease: Relationship of Cognition and Behavior to Neurochemistry

1992 ◽  
Vol 4 (3) ◽  
pp. 71-78 ◽  
Author(s):  
Peter J. Whitehouse
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neural Systems ◽  
Neurotransmitter Systems ◽  
Methodological Problems ◽  
Behavioral Impairments ◽  
And Behavior ◽  
Relationship Of

Alzheimer's disease is characterized by loss of cells and synapses in specific neural systems. The development of more effective therapies will depend on understanding the relationships between this pathology and the cognitive and behavioral impairments. In this review, focusing primarily on work in our laboratory, we will examine both classic and neuropeptide neurotransmitter systems and will discuss conceptual and methodological problems in relating clinical and biological measures.

Undernutrition and the development of brain neurotransmitter systems

Life Sciences ◽  
1984 ◽  
Vol 35 (21) ◽  
pp. 2085-2094 ◽  
Author(s):  
R.C. Wiggins ◽  
Gregory Fuller ◽  
S.J. Enna
Keyword(s):  
Neurotransmitter Systems ◽  
Brain Neurotransmitter

scholarly journals Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2486 ◽  
Author(s):  
Willem G. van Ginkel ◽  
Danique van Vliet ◽  
Els van der Goot ◽  
Martijn H. J. R. Faassen ◽  
Arndt Vogel ◽  
...  
Keyword(s):  
Degradation Pathway ◽  
Behavioral Differences ◽  
Normal Range ◽  
Neurocognitive Impairments ◽  
Brain Neurotransmitter ◽  
Mice Brain ◽  
Tyrosinemia Type 1 ◽  
Fumarylacetoacetate Hydrolase ◽  
And Behavior

Tyrosinemia type 1 (TT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Neurocognitive deficiencies have been described in TT1 patients, that have, among others, been related to changes in plasma large neutral amino acids (LNAA) that could result in changes in brain LNAA and neurotransmitter concentrations. Therefore, this project aimed to investigate plasma and brain LNAA, brain neurotransmitter concentrations and behavior in C57 Bl/6 fumarylacetoacetate hydrolase deficient (FAH−/−) mice treated with 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and/or diet and wild-type mice. Plasma and brain tyrosine concentrations were clearly increased in all NTBC treated animals, even with diet (p < 0.001). Plasma and brain phenylalanine concentrations tended to be lower in all FAH−/− mice. Other brain LNAA, were often slightly lower in NTBC treated FAH−/− mice. Brain neurotransmitter concentrations were usually within a normal range, although serotonin was negatively correlated with brain tyrosine concentrations (p < 0.001). No clear behavioral differences between the different groups of mice could be found. To conclude, this is the first study measuring plasma and brain biochemistry in FAH−/− mice. Clear changes in plasma and brain LNAA have been shown. Further research should be done to relate the biochemical changes to neurocognitive impairments in TT1 patients.

Autoantibodies in autoimmune polyglandular syndrome type I patients react with major brain neurotransmitter systems

2009 ◽  
Vol 513 (1) ◽  
pp. 1-20 ◽  
Author(s):  
Sergueï O. Fetissov ◽  
Sophie Bensing ◽  
Jan Mulder ◽  
Erwan Le Maitre ◽  
Anna-Lena Hulting ◽  
...  
Keyword(s):  
Type I ◽  
Syndrome Type ◽  
Neurotransmitter Systems ◽  
Autoimmune Polyglandular Syndrome ◽  
Brain Neurotransmitter ◽  
Autoimmune Polyglandular Syndrome Type
Sign in / Sign up

Export Citation Format

Share Document